Peter Paul Platenburg

LiteVax BV is a biopharmaceutical company focusing on the development and exploitation of novel human vaccine adjuvant products. Our lead adjuvant candidate CMS outperforms commercially available alternatives with a higher efficacy without overt toxicity, allowing vaccine production at much lower costs and efficacy of one-shot applications. We are in the clinical stage of development with a second clinical trial started in February 2024 focusing on an improved influenza vaccine for the older population.